课题基金 / 基金详情

Malaria Vaccine Development Unit (mvdu)

Malaria Vaccine Development Unit (mvdu)
疟疾疫苗开发单位 (mvdu)
批准号：
6669602
负责人：
Louis Miller
金额：
$0.0万
依托单位：
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/6669602
关键词：
Anopheles Aotus Macaca mulatta Plasmodium bacterial antigens biomedical facility clinical trial phase I helminthic antigen human subject human therapy evaluation immunization laboratory mouse malaria malaria vaccines nonhuman therapy evaluation parasitism patient oriented research protein engineering protein purification protein structure function protozoal antigen recombinant proteins vaccine development

项目摘要

项目成果

Louis Miller的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Malaria Vaccine Development Unit (MVDU) General Description: The Malaria Vaccine Development Unit (MVDU) is an NIAID initiative in close collaboration with DMID to respond to the global need for vaccines against malaria. This effort has been given additional impetus during the past year by the attention focused on this issue by Dr. Anthony Fauci, Director, NIAID, and by support for malaria announced by the Bill and Melinda Gates Foundation. The MVDU opened officially on May 6, 2001. We now have produced six cGMP products: AMA1 FVO, AMA1 3D7, MSP1(42) FVO, MSP1(42) 3D7, Pfs25, Pvs25. We are developing process for two more products: Pfs48 and Pvs48. We have completed the IND for Pvs25 and will soon submit the IND for AMA1 FVO and AMA1. This means that we will be entering trials with Pvs25 this year and AMA1 next year. The whole unit is now converted to an industrial type lab with the institution of industrial type control on quality.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MALARIA VACCINE DEVELOPMENT UNIT (MVDU)
Malaria Parasite Ligands And Host Cell Receptors
Malaria Vaccines: BSAM-1/ALHYDROGEL + CPG 7909
Malaria Vaccines: AMA1-C1/ISA 720
海外基金